SPCC shared on LinkedIn:
“Save the date for our next live session: ‘Overview and clarification of the current HR+ HER2- EBC treatment landscape’.
Topics:
∙ Clarification of current treatment guidelines – perspectives of clinical implementation?
∙ Benefit/cost ratio of treatment escalation and diagnostic steps vs recurrence risk
27 November – 18:00 CET
Register here.
This webinar is supported by an unrestricted educational grant from Eli Lilly.”
